BrainStorm Advances NurOwn ALS Program Toward Phase 3b
New York, United States, August 14, 2026 BrainStorm Cell Therapeutics Inc. announced its financial results for the second quarter...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
New York, United States, August 14, 2026 BrainStorm Cell Therapeutics Inc. announced its financial results for the second quarter...
Tokyo, Japan, August 16, 2026 Kyowa Kirin Co., Ltd. has selected Cognizant and Benchling as partners to implement an...
New York, United States, August 14, 2026 Actinium Pharmaceuticals, Inc. announced new intellectual property and manufacturing developments supporting its...
